J INTS BIO is a bioscience company focused on developing anticancer and orphan drugs, utilizing a streamlined regulatory process to expedite drug availability. Their pipeline includes targeted therapies for non-small cell lung cancer, glioblastoma, and various types of breast, ovarian, and pancreatic cancers, providing cost-effective treatment options for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers, including non-small cell lung cancer, glioblastoma, and breast, ovarian, and pancreatic cancers, lack effective and affordable targeted therapies, leaving patients with limited treatment options. The traditional drug development pathway is often lengthy and expensive, delaying access to potentially life-saving medications.
Solution
J INTS BIO is a biopharmaceutical company focused on developing targeted anticancer and orphan drugs through an efficient regulatory process. Their pipeline includes therapies designed to address unmet needs in cancers such as non-small cell lung cancer and glioblastoma. By streamlining development and regulatory pathways, J INTS BIO aims to deliver cost-effective treatment options to patients more rapidly.
Target Audience
The primary target audience includes patients with cancers such as non-small cell lung cancer, glioblastoma, and breast, ovarian, and pancreatic cancers, as well as healthcare providers seeking more effective and affordable treatment options.
Features
- Focus on targeted therapies for cancers with limited treatment options
- Streamlined regulatory approach to accelerate drug availability
- Pipeline includes treatments for non-small cell lung cancer, glioblastoma, and various other cancers
- Development of cost-effective treatment options